Literature DB >> 35471043

Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales.

Stuart Shapiro1.   

Abstract

Entities:  

Keywords:  ESBL; cefepime; enmetazobactam; β-lactamase inhibitors

Mesh：

Substances：

Year:  2022        PMID： 35471043      PMCID： PMC9112890          DOI： 10.1128/aac.00298-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


× No keyword cloud information.
  7 in total

1.  Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam-β-Lactamase Inhibitor Combination.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Jocelyne Caillon; Melissa D Barnes; Gilles Potel; Saralee Bajaksouzian; Joseph D Rutter; Amokrane Reghal; Stuart Shapiro; Magdalena A Taracila; Michael R Jacobs; Robert A Bonomo; Cédric Jacqueline
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019.

Authors:  James A Karlowsky; Sibylle H Lob; C Andrew DeRyke; Fakhar Siddiqui; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2022-01-26       Impact factor: 5.283

3.  Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales.

Authors:  Juan Carlos Vázquez-Ucha; Cristina Lasarte-Monterrubio; Paula Guijarro-Sánchez; German Bou; Alejandro Beceiro; Marina Oviaño; Laura Álvarez-Fraga; Isaac Alonso-García; Jorge Arca-Suárez
Journal:  Antimicrob Agents Chemother       Date:  2021-11-22       Impact factor: 5.938

4.  Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Krystyna M Kazmierczak; Sharon Rabine; Meredith Hackel; Robert E McLaughlin; Douglas J Biedenbach; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

5.  Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.

Authors:  Krystyna M Kazmierczak; James A Karlowsky; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

6.  In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.

Authors:  Ian Morrissey; Sophie Magnet; Stephen Hawser; Stuart Shapiro; Philipp Knechtle
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  Sigmoid Emax Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime.

Authors:  Philipp Knechtle; Stuart Shapiro; Ian Morrissey; Cyntia De Piano; Adam Belley
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191
  7 in total
  1 in total

1.  Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales".

Authors:  Juan Carlos Vázquez-Ucha; Cristina Lasarte-Monterrubio; Paula Guijarro-Sánchez; Marina Oviaño; Laura Álvarez-Fraga; Isaac Alonso-García; Jorge Arca-Suárez; German Bou; Alejandro Beceiro
Journal:  Antimicrob Agents Chemother       Date:  2022-04-26       Impact factor: 5.938
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.